InMed Pharmaceuticals Inc. - 10-Q Filing

InMed Pharmaceuticals reports Q3 2026 results amid proposed merger with Mentari and winding down of BayMedica segment.

SEC EDGAR ·

Tickers: $INM

Read the full article at SEC EDGAR

More Regulatory news